Search
Search Results
##search.searchResults.foundPlural##
-
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
3854Suppl. Files: 1089PDF: 1052Html: 165 -
THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
4051PDF: 1923HTML: 1754 -
MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESIVE TREATMENT
823PDF: 485HTML: 1292 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4750PDF: 1753HTML: 2696Untitled: 210 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3257PDF: 1335HTML: 2618 -
HEPATITIS C VIRUS INFECTION AND LYMPHOMA
959PDF: 527HTML: 7803 -
IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY. ITP and COVID19 infection and vaccination
1386PDF: 794HTML: 303 -
Refractory Immune Thrombocytopenic Purpura and Cytomegalovirus Infection: A Call for a Change in the Current Guidelines
4223PDF: 1163HTML: 2143Figure 1: 161 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4200PDF: 1511HTML: 440 -
Tenofovir as Rescue Therapy Following Clinical Failure to Lamivudine in Severe Acute Hepatitis B
2101PDF: 809HTML: 1633Figure 1: 237 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
2613PDF: 1068HTML: 105 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
2903PDF: 966HTML: 2056Cover letter: 174 -
Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era Antiviral and monoclonal Antibodies in Haematological Patients in the omicron era
1261PDF: 926HTML: 85 -
Cardiac toxicity associated with HCV direct antiviral agents Heart in HCV DAAs therapy
1560PDF: 959HTML: 177 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1274PDF: 1002HTML: 112 -
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment
1905PDF: 1149HTML: 262 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2047PDF: 1500HTML: 265 -
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
954PDF: 528HTML: 716 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2570PDF: 1600HTML: 2346Table1: 187 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
3872PDF: 1088HTML: 424 -
Severe Acute Hepatitis B Treated with Entecavir
1496PDF: 779HTML: 2466Figure: 164Title page: 170disclosure: 102 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1590PDF: 791HTML: 846jdoe, table 2 infections CML .doc: 188jdoe, table 1 infections CML .doc: 174 -
APLASTIC ANEMIA AND VIRAL HEPATITIS
1241PDF: 525HTML: 23029 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1440PDF: 757HTML: 196 -
FROM LEGACY TO INNOVATION: PIDOTIMOD’S EXPANDING THERAPEUTIC HORIZON Pidotimod: Revisiting a Classic Immunomodulator
2336PDF: 892HTML: 406 -
IMPLEMENTATION OF MICROELIMINATION STRATEGY IN ERADICATION OF CHRONIC HEPATITIS C INFECTION IN PATIENTS WITH HEMOPHILIA IN THE NORTHERN REGION OF SERBIA Microelimination Strategy of Chronic Hepatitis C Infection in patients with Hemophilia
833PDF: 340HTML: 143 -
-
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2211PDF: 928HTML: 290







